Program
tobevibart
Also written as “VIR-3434” and “Tobevibart”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis · Fibrosis · Hepatitis D, Chronic, led by 2 companies.
Drug pageTobevibart: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vir Biotechnologyits history only | 84 open or running | phase 3since Mar 24, 2025 | May 25, 2020 | Dec 2026phase 3 · NCT07128550 |
| Virion Therapeutics | 10 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Virion Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 21, 2022Named tobevibartINNProposed as its International Nonproprietary Name in WHO's List 127 · before, VIR-3434
- Sep 20, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06070051 · 35 enrolled · Hong Kong, New Zealand
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Virion Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06070051Hepatitis B, Chronic · Hong Kong, New Zealand | 1 | Completed | Mar 31, 2026 | 35 |
How it is read
Names in the registry
- “VIR-3434”, 6 entries
- “Tobevibart”, 3 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
- Hepatitis, 3 studies
- Fibrosis, 1 study
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.